Balaxi Pharmaceuticals Limited has informed the Exchange regarding the outcome of their board meeting, which includes the approval of the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2023, as well as an update on the companys pharmaceutical formulation plant.